Roche Gets Positive CHMP Review for Tarceva as First-line Treatment in EGFR-mutated NSCLC | GenomeWeb

Originally published July 22. This article has been updated to include information on Roche/Genentech's data submission plans for Tarceva to UK's NICE.

By Turna Ray

Following a positive opinion this week from the European Medicines Agency's Committee for Medicinal Products for Human Use, Roche is hoping that the European Commission will approve its application to expand Tarceva's use as a front-line non-small cell lung cancer treatment in patients with EGFR mutations.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.